Spyre Therapeutics, Inc. (SYRE)
85.69
+5.79
(+7.25%)
USD |
NASDAQ |
Oct 09, 16:00
85.71
+0.02
(+0.02%)
Pre-Market: 20:00
Spyre Therapeutics Cash from Operations (Quarterly) : -70.16M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -70.16M |
| March 31, 2026 | -57.54M |
| December 31, 2025 | -44.65M |
| September 30, 2025 | -37.12M |
| June 30, 2025 | -46.56M |
| March 31, 2025 | -41.09M |
| December 31, 2024 | -37.53M |
| September 30, 2024 | -29.50M |
| June 30, 2024 | -62.25M |
| March 31, 2024 | -28.54M |
| December 31, 2023 | -31.04M |
| September 30, 2023 | -34.60M |
| June 30, 2023 | -16.64M |
| March 31, 2023 | -17.63M |
| December 31, 2022 | -18.14M |
| September 30, 2022 | -15.07M |
| June 30, 2022 | -20.67M |
| March 31, 2022 | -26.26M |
| December 31, 2021 | -19.27M |
| September 30, 2021 | -17.00M |
| June 30, 2021 | 2.082M |
| March 31, 2021 | -19.53M |
| December 31, 2020 | -17.13M |
| Date | Value |
|---|---|
| September 30, 2020 | -17.54M |
| June 30, 2020 | -19.41M |
| March 31, 2020 | -21.69M |
| December 31, 2019 | -16.29M |
| September 30, 2019 | -17.21M |
| June 30, 2019 | -16.38M |
| March 31, 2019 | -15.81M |
| December 31, 2018 | -7.20M |
| September 30, 2018 | -8.502M |
| June 30, 2018 | -9.044M |
| March 31, 2018 | -7.447M |
| December 31, 2017 | -5.873M |
| September 30, 2017 | -7.368M |
| June 30, 2017 | -5.942M |
| March 31, 2017 | -5.432M |
| December 31, 2016 | -4.355M |
| September 30, 2016 | -5.865M |
| June 30, 2016 | -4.632M |
| March 31, 2016 | -3.988M |
| December 31, 2015 | -0.833M |
| September 30, 2015 | -3.811M |
| June 30, 2015 | -3.855M |
| March 31, 2015 | -2.483M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| AbbVie, Inc. | 3.436B |
| Incyte Corp. | 507.66M |
| SELLAS Life Sciences Group, Inc. | -7.588M |
| Relay Therapeutics, Inc. | -54.11M |
| ACADIA Pharmaceuticals, Inc. | 100.78M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -297.90M |
| Cash from Financing (Quarterly) | 432.89M |
| Free Cash Flow | -209.47M |
| Free Cash Flow Per Share (Quarterly) | -0.828 |
| Free Cash Flow to Equity (Quarterly) | -70.16M |
| Free Cash Flow to Firm (Quarterly) | -70.16M |
| Free Cash Flow Yield | -3.27% |